Ethic Inc. Has $1.79 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Ethic Inc. lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,975 shares of the medical equipment provider's stock after selling 3,521 shares during the period. Ethic Inc.'s holdings in Zimmer Biomet were worth $1,793,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Stonebridge Financial Group LLC acquired a new position in Zimmer Biomet in the 4th quarter valued at $25,000. Accredited Wealth Management LLC bought a new stake in Zimmer Biomet during the fourth quarter valued at about $36,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $39,000. OFI Invest Asset Management bought a new position in shares of Zimmer Biomet in the fourth quarter worth about $40,000. Finally, Dunhill Financial LLC lifted its position in shares of Zimmer Biomet by 86.6% during the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock worth $47,000 after purchasing an additional 206 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $98.18 on Tuesday. The stock's fifty day simple moving average is $104.30 and its 200 day simple moving average is $106.10. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $122.25. The firm has a market cap of $19.42 billion, a price-to-earnings ratio of 22.06, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.94 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.98%. Zimmer Biomet's dividend payout ratio is 21.24%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 6th. Canaccord Genuity Group cut their target price on shares of Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday. JPMorgan Chase & Co. decreased their price target on shares of Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley dropped their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Finally, Barclays reduced their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $113.45.

Insider Activity

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.39% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.